Recommended

Teva close to API business sale
Streamlined rAAV purification enables efficient upstream analytics – access now
First new IPF treatment in US for a decade
Webinar: Radiopharmaceuticals’ time-to-result challenge
AstraZeneca/Daiichi cancer drug boost
Takeda to move away from cell therapy
GSK appoints new CEO
news

CDMO to manufacture SARS-CoV-2 intranasal vaccine

3
SHARES

In a collaboration between the Institutes of Health (NIH) and CDMO Exothera, an intranasal vaccine for SARS-CoV-2 will be manufactured for use in a clinical Phase I/II trial in Africa and the US.

CDMO to manufacture SARS-CoV-2 intranasal vaccine for COVID-19

The National Institutes of Health (NIH) has chosen contract research, development, and manufacturing organisation (CRDMO) Exothera SA to develop the manufacturing process for its intranasal vaccine against SARS-CoV-2 coronavirus to treat COVID-19.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

As an alternative drug delivery method to traditional injected vaccines, live, replicating, intranasal vaccines have potential for effectively interrupting transmission of COVID-19 by inducing the development of immunity in the respiratory tract.

Intranasal vaccines have previously been used to immunise against conditions such as respiratory viruses, measles and rubella.

NIH’s vaccine candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials, produced in an A549 cell line.

MHRA authorises new COVID-19 vaccine

What will the intranasal vaccine manufacturing project involve?

Exothera will generate current good manufacturing practice (cGMP) material using NIH’s current manufacturing and analytical processes for use in US and African Phase I/II clinical trials.

Prior to manufacture in Exothera’s good manufacturing (GMP) facility in Jumet, Belgium—tech transfer, stability study, CMC study, AS development and QC testing of the intranasal vaccine will be conducted. The Belgian facility is one of the biggest dedicated viral vectors plants in Europe. It can facilitate projects from development through to commercial manufacturing.

Exothera is dedicated to viral vector and nucleic acids production. Hanna Lesch, the company’s Chief Technology Officer announced that it is “proud NIH selected us for this project”.

As part of the Cooperative Research and Development Agreement (CRADA), researchers from Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Dartmouth’s Geisel School of Medicine will also be part of the intranasal vaccine manufacturing project.

“We are pleased to join this collaborative effort to develop and assess the safety, immunogenicity, and effectiveness of an adenovirus type 4-based vaccine expressing the SARS-CoV-2 spike protein as a novel approach to the prevention of COVID-19,” commented Dr Peter Wright, infectious disease, and international health physician at Dartmouth Health’s Dartmouth Hitchcock Medical Center (DHMC) and Professor of Paediatrics at Dartmouth’s Geisel School of Medicine.

Share via
Share via